A considerable fraction of families with HNPCC shows no germline mismatch repair (MMR) gene mutations. We previously detected 'hidden' MMR gene defects in 42% of such families, leaving the remaining 58% 'truly' mutation negative. Here, we characterized 50 colorectal carcinomas and five adenomas arising in HNPCC families; 24 truly MMR gene mutation negative and 31 MMR gene mutation positive. Among 31 tumors from MMR gene mutation positive families, 25 (81%) had active Wnt signaling as indicated by aberrant b-catenin localization with or without CTNNB1 mutations, compared to only 7/ 18 tumors from MMR gene mutation negative families (39%; P ¼ 0.005). CGH studies revealed stable profiles in 9/16 (56%) of MMR gene mutation negative tumors, which was significantly associated with membranous b-catenin (P ¼ 0.005). Tumors with membranous b-catenin from the MMR gene mutation negative group also showed low frequency of TP53 mutations compared to those with nuclear b-catenin. Thus, a majority of the MMR gene mutation negative cases exhibited a novel molecular pattern characterized by the paucity of changes in common pathways to colorectal carcinogenesis. This feature distinguishes the MMR gene mutation negative families from both HNPCC families linked to MMR defects and sporadic cases, suggesting the involvement of novel predisposition genes and pathways in such families.
Introduction
Up to 50% of hereditary nonpolyposis colorectal cancer (HNPCC) families meeting the stringent Amsterdam I criteria (Vasen et al., 1991) have no detectable mutations in the 'major' DNA mismatch repair (MMR) genes and an even greater fraction (around 70%) of families not meeting these criteria fails to show such mutations (Nystro¨m-Lahti et al., 1996; Wijnen et al., 1997) . We recently demonstrated that 42% of HNPCC families that had screened mutation negative by conventional methods could be attributed to 'hidden' defects in the major MMR genes (Renkonen et al., 2003) , while the nature of the predisposing defects in the remaining families remains elusive.
Common genetic pathways in colorectal carcinogenesis involve deregulation of the Wnt pathway, mainly due to APC mutations (Huang et al., 1996; Morin et al., 1997; Rowan et al., 2000) . KRAS and TP53 mutations are subsequent common events (Konishi et al., 1996; Salahshor et al., 1999) . In addition to HNPCC tumors, MMR genes are implicated in around 15% of sporadic colorectal cancers showing instability at repetitive DNA sequences (microsatellite instability, MSI) (Peltoma¨ki, 2003) . In MSI tumors, Wnt pathway abnormalities show a shift from APC to CTNNB1 (b-catenin gene) involvement (Miyaki et al., 1999; Rowan et al., 2000) . In microsatellite stable (MSS) colorectal carcinomas, gross chromosomal structural and numerical changes are major features and such carcinoma cells show progressive karyotypic clonal divergence during tumor growth (chromosomal instability, CIN) (Lengauer et al., 1997; Abdel-Rahman et al., 2001 ). Consequently, two major carcinogenic pathways with some overlap have been proposed: the MSS/CIN þ and the MSI/CINÀ (Lengauer et al., 1997; Abdel-Rahman et al., 2001) .
Not all colorectal cancers comply with the above main model. For example, a report suggested the existence of an additional group of microsatellite stable and chromosomally stable colorectal cancers with a tendency to young age or familial clustering (Chan et al., 2001 ). We performed a comprehensive molecular and DNA copy number analysis on colorectal carcinomas arising in cohorts of families with clinical features of HNPCC. As shown here, detailed tracing of molecular events in such special cohorts may unravel novel pathways to colorectal carcinogenesis.
Results

MSI and MMR gene expression
Among the MMR gene mutation negative colon tumors (Table 1) , 22/24 were MSS with normal expression of the MLH1, MSH2, and MSH6. Two tumors showed MSI and of these one (34:2) showed complete loss of MLH1 and another (32:1) showed positive but weaker staining of MLH1 compared to its matching normal mucosa (MSH2 and MSH6 were normally expressed in both). These two cases were included here because similar changes were not observed in other family members (34:1, 32:2) and MLH1 promotor methylation was observed in tumor tissues (data not shown) supporting a sporadic rather than hereditary nature of these changes. The 31 MMR gene mutation positive colon carcinomas were known to have high-degree microsatellite instability (MSI-H) and immunohistochemical loss of the respective protein (Table 2; Schweizer et al., 2001; Kuismanen et al., 2002 and unpublished data) .
Wnt signaling
Tissue sections were available from 18/24 MMR gene mutation negative tumors for immunohistochemistry (IHC) analysis. b-Catenin showed membranous expression pattern in all normal colonic epithelial cells. Seven tumors out of 18 (39%) showed nuclear b-catenin in 20-90% of tumor cells indicating Wnt signaling deregulation. No CTNNB1 mutations were identified in any of these seven tumors or in the remaining 17 MMR gene mutation negative tumors (Table 1) . Among the seven tumors with nuclear b-catenin, IHC loss of APC expression was observed in six (data not shown) and comparative genomic hybridization (CGH) and/or loss of heterozygosity (LOH) analysis revealed chromosomal loss of the APC locus on chromosome 5q22 in four of these tumors (Tables 3 and 4 ).
In the MMR gene mutation positive tumors, aberrant b-catenin was observed in 25 (21 nuclear in 20-100% and four cytoplasmic in >50% of tumor cells) out of 31 carcinomas (81%; Kariola et al., 2005) . Nine of these 25 tumors (36%) could be explained by mutations in the CTNNB1 exon 3 (Table 2 ), all of which were known pathogenic activating mutations within the regulatory domain (Sparks et al., 1998; Rowan et al., 2000) .
The frequency of 61% of tumors showing membranous b-catenin within the MMR gene mutation negative tumors was significantly higher compared to the 19% frequency in the MMR gene mutation positive tumors (P ¼ 0.005). 
CDX2
CDX2 IHC showed strong nuclear staining in all normal colonic epithelial cells. Tumor-specific CDX2 expression changes (complete or partial loss) were observed in 2/18 (11%) and 2/31 (6%) among the MMR gene mutation negative and positive groups, respectively (Tables 1 and 2 ). CDX2 expression changes did not correlate with b-catenin activation status. CDX2 exon 3, which contains most of the reported pathogenic Total number of CGH changes was counted for chromosome arms so that a gain or loss of a whole chromosome is considered as two events for this purpose (Chan et al., 2001) . According to this number, cases were divided into CINÀ and CIN+ subgroups (above and below the middle line respectively, see Results) (Wicking et al., 1998; Yagi et al., 1999) , was sequenced for possible mutations, without finding any.
KRAS and BRAF mutation analysis
In the MMR gene mutation negative tumors, KRAS exon 2 mutations were identified in 4/23 (17%) and the BRAF V600E mutation, previously known as V599E (Kumar et al., 2003) , in one (4%; Table 1 ). KRAS mutations were identified in 8/30 (26%) MMR gene mutation positive tumors, while no BRAF mutations were observed in this group (Table 2 ). All KRAS mutations identified in the MMR gene mutation negative tumors were at codon 12 and no codon 13 mutation was present in this group in contrast with tumors from the MMR gene mutation positive group.
p53 expression and TP53 mutation analysis
In the MMR gene mutation negative group, p53 protein stabilization was observed in 8/18 (44%) tumors and pathogenic mutations were identified in five of these eight tumors (Table 1) as well as in an additional tumor (45:1) from which no section was available for IHC. Stabilization of the p53 protein was observed in 4/31 carcinomas (13%) from the MMR gene mutation positive group and pathogenic TP53 mutations were identified in all of these four tumors ( Table 2 ). The frequency of p53 protein stabilization was significantly higher (P ¼ 0.02) in the MMR gene mutation negative group compared to the MMR gene mutation positive group, but there was no significant difference between the two groups regarding the frequency of TP53 mutation.
CGH
Previous CGH studies have shown the virtual absence of gross chromosomal gains and losses in MSI þ colon carcinomas (Schlegel et al., 1995; Chan et al., 2001) ; we therefore focused on the MMR gene mutation negative group. High quality DNA suitable for performing CGH was available from 16 MMR gene mutation negative tumors. Table 3 shows detailed description of the CGH results. We used a cutoff level of 5 or more events of chromosome arm gain or loss to classify a case as CIN þ (Chan et al., 2001) . This level clearly separated the cases into two groups: a stable (CINÀ) group (9/16, 56%) with the number of chromosome arm gains or losses ranging from 0 to 4 with a mean of 1; and an unstable (CIN þ ) group (7/16, 44%) with the number of chromosome arm gains or losses ranging from 7 to 18 with a mean of 10.6. The most frequent changes were À18q, þ 20q, À5q, þ 20p in order of frequency; of these, only À5q was specific to the CIN þ group. 18q loss was associated with TP53 mutations (P ¼ 0.011).
The range and detail of chromosomal aberrations were closely similar to those described in previous reports (Schlegel et al., 1995; Abdel-Rahman et al., 2001; Chan et al., 2001 , and the percentages for combined strict and putative LOH were 52 vs 28%, respectively (P ¼ 0.034, df ¼ 14). Table 5 summarizes the essential molecular findings in the present HNPCC tumors and the data are compared to those obtained from sporadic colorectal cancers (MSS where possible). Figure 1 shows the interrelations of individual changes in the MMR gene mutation negative (a) and mutation positive groups (b). The most remarkable observation here was the association of colorectal carcinomas from a well-scrutinized series of MMR gene mutation negative families with the paucity of common molecular and chromosomal alterations characteristic of colorectal carcinogenesis.
Discussion
Inactive Wnt pathway (membranous b-catenin) -a frequent finding compared to other hereditary or sporadic (MSI or MSS) colorectal cancers
The overwhelming majority of colorectal cancers display active Wnt signaling due to either APC or CTNNB1 mutations (Morin et al., 1997; Sparks et al., 1998; Rowan et al., 2000) . APC mutations were reported to occur in 75% of MSS and 56% of MSI colorectal cancers and their frequency in MSI colorectal cancers was the same regardless of whether the tumors were from sporadic or HNPCC cases (Huang et al., 1996) . CTNNB1 mutations were specific to MSI colorectal cancers, in which their frequency ranged from 25%
(Mirabelli-Primdahl et al., 1999) to 43% (Miyaki et al., 1999) , and all CTNNB1 mutant tumors had intact APC gene. The subsequent use of IHC to analyse b-catenin subcellular localization has proven successful in detecting nuclear b-catenin as a marker for Wnt signaling activation (Iwamoto et al., 2000; Hinoi et al., 2001; Hao et al., 2002) . Nuclear b-catenin expression was detected in 79% (Hao et al., 2002) to 100% (Iwamoto et al., 2000) of colorectal cancers not characterized for MSI. While the frequencies we observed for b-catenin alterations in our MMR gene mutation positive HNPCC families were compatible with previous literature reports, the MMR gene mutation negative group was unique in having inactive Wnt signaling (indicated by membranous b-catenin and supported by the absence of CTNNB1 mutations and any loss at 5q by CGH) in a majority of tumors (11/18, 61%, or 9/16, 56%, if the two adenomas were excluded). We found that CDX2 alteration did not account for such lack of APC/b-catenin deregulation in contrast to a previous report (da Costa et al., 1999) . Qualtrough et al. (2002) also noted that CDX2 expression status in colorectal adenoma cell lines was independent of their APC status.
High frequency of MSS carcinomas with stable chromosomes
It is well established that there is an inverse relation between MSI and chromosomal instability. Accordingly, marked stability of chromosome number and structure (measured by karyotyping or CGH) was associated with mismatch repair defects in both sporadic (Schlegel et al., 1995; Curtis et al., 2000; Abdel-Rahman et al., 2001) and HNPCC-related (Muleris et al., 1995) colorectal carcinomas. This association holds even when there is clear proof of active Wnt signaling due to APC or CTNNB1 mutations in these tumors (Abdel-Rahman et al., 2001 ; see also Rowan et al. (2000) for the APC/ CTNNB1 status in MSI cell lines). On the other hand, the majority of MSS colorectal carcinomas are chromosomally unstable (Abdel-Rahman et al., 2001; Leslie et al., 2003) . Omitting the colorectal adenomas (33:1, 79:1), our MMR gene mutation negative series showed seven chromosomally stable (CINÀ) carcinomas among 14 MSS carcinomas (50%) examined by CGH. This high frequency of stable carcinomas was highly significant when compared to published data on sporadic MSS colorectal cancers (P ¼ 0.006; Table 5 ) or xenografted MSS colorectal cancers (2/27, P ¼ 0.004; Curtis et al., 2000) .
Recently, Chan et al. (2001) have drawn attention to a group of colorectal cancers with near diploid DNA, few examples of chromosome imbalances, and stable microsatellite DNA. The proportion of such cancers was significantly higher in early-onset (less than 45 years) tumors, and some were associated with a positive family history. Tumors from our MMR gene mutation negative families with stability of both microsatellites and chromosomes were associated with a relatively late mean age at onset (53.7 years) and had an even more remarkable molecular profile (rarity of changes characteristic of colorectal tumorigenesis). It is possible, by analogy with MSI and CIN that such 'stable' tumors also possess a form of genomic instability, albeit undetectable by the methods used. For example, our recent work on colorectal cancer cell lines using Spectral Karyotyping, a 24-color fluorescent in situ hybridization (FISH) technique, revealed a novel chromosomal instability phenotype characterized by an ongoing tendency to multiple reciprocal chromosomal translocations while CGH, as expected, did not reveal such defects (Abdel-Rahman et al., 2001) .
Rarity of TP53 mutations in tumors with inactive Wnt signaling
The nine MMR gene mutation negative colon cancers lacking Wnt activation (20:1, 31:1, 32:1, 32:2, 34:2, 48:1, 49:1, 56:1, 75:1) were also distinguished by the absence of chromosomal instability (see above) and absence of TP53 mutations. As a finding unique to this group, three carcinomas showed p53 stabilization by IHC despite the lack of TP53 mutations. Such phenomenon was previously observed in some tumors including colorectal carcinomas (Costa et al., 1995) . Failure of p53 degradation due to disruption of the p53-Mdm2 negative feedback loop provides a plausible explanation for p53 stabilization in TP53 wild-type tumors (Vogelstein et al., 2000) .
These findings were significantly different from those observed in colon cancers from the MMR gene mutation positive families (Table 5) . We searched the literature for comparable sets of data on MSS or unselected colorectal cancers for evaluation of the frequency of such 'stable' carcinomas. In a series of 50 unselected colorectal carcinomas (Leslie et al., 2003) , 'stable' tumors (defined by the absence of APC and TP53 mutations and less than six CGH gains or losses) were observed at a frequency of 3/50 (6% and one of these 3 had MSI-H with MLH1 loss). The difference was highly significant (P ¼ 0.00008) when compared to our MMR gene mutation negative cancers (9/17, 56%).
Collectively, our data divide the MMR gene mutation negative cancers into two subgroups. The majority shows membranous b-catenin, a tendency to affect the right colon, younger age of onset (mean 53.7 years), and novel molecular features including stable microsatellites and chromosomes and infrequent TP53 mutations. The minority shows nuclear b-catenin, predominance of left colon tumors, later age of onset (mean 58.6), and molecular features similar to classical MSS/CIN þ sporadic colorectal cancers. These findings provide new insights into the mechanisms of colorectal carcinogenesis in a cohort not linked to germline mutations in MMR genes and warrant similar studies in larger series of families.
Materials and methods
Patients and samples
This investigation was based on colorectal tumors from wellcharacterized families from the Hereditary Colon Cancer Registry of Finland. The families had verified or putative HNPCC according to the Amsterdam (Vasen et al., 1991 (Vasen et al., , 1999 or Bethesda criteria (Rodriguez-Bigas et al., 1997) and had been included in mutation analyses based on clinical and family criteria.
In total, 24 MMR gene mutation negative colorectal tumors were from 19 families that had screened negative for mismatch repair gene MSH2, MLH1, MSH6, PMS1, and PMS2 mutation by multiple techniques (Nystro¨m-Lahti et al., 1996; Holmberg et al., 1998; Huang et al., 2001; Liu et al., 2001) . Additionally, mutation 1, a common founder mutation in the Finnish population, was excluded using a specific test (Nystro¨m-Lahti et al., 1995) . Of these families, 15 were scrutinized before (Renkonen et al., 2003) , and four families scrutinized in this work by mismatch repair gene expression and MSI analysis to exclude any possibility of hidden mutations in the mismatch repair genes. All families showed a dominant pattern of inheritance arguing against recessive syndromes such as MYH polyposis, and no excessive adenomas or other clinical manifestations suggestive of familial adenomatous polyposis or its variants were present. The 31 MMR gene mutation positive tumors were from verified HNPCC families segregating germline mutations in the mismatch repair genes MLH1 or MSH2 (Nystro¨m-Lahti et al., 1996; Holmberg et al., 1998) . The MLH1 mutations (nos. 1-3 and 5-8) and the MSH2 mutation (no. 9) were as follows: mutation 1, 3.5-kb genomic deletion of exon 16 and flanking introns; mutation 2, g-a at 454-1 at splice acceptor of exon 6; mutation 3, G-C at 1976 (codon 659) of exon 17; mutation 5, T-G at 320 (codon 107) of exon 4; mutation 6, g-a at 1039-1 at splice acceptor of exon 12; mutation 7, g-t at 1559-1 at splice acceptor of exon 14; mutation 8, C-T at 1975 (codon 659) in exon 17, and mutation 9, deletion of CA at 1550 (codon 518) of exon 10.
The MMR gene mutation negative group showed a predominance of left sided and rectal tumors and 53.7 years average age at tumor diagnosis, as compared to mostly rightsided tumors and 45.2 years average age at cancer diagnosis in the mismatch repair gene mutation positive group. There was no statistically significant difference in the tumor grade and stage between the two groups.
Fresh frozen and/or paraffin-derived specimens of tumor and matching normal tissues were collected from pathology departments of different hospitals and used for IHC analysis and DNA extraction. Areas with pure normal or high tumor percentages, with minimal intervening stroma or inflammatory cells, were selected and verified histologically and subsequently dissected out for DNA preparation. Tumor percentages ranged between 50 and 90%. In some cases, blood was also available for genomic DNA extraction. All human specimens were obtained after informed consent and approvals from the appropriate institutional review boards of the Helsinki University Central Hospital.
IHC
Sections (4 mm) from formalin-fixed paraffin-embedded tissues were mounted on silanized slides (Dako, Glostrup, Denmark) and air-dried overnight at 371C. After dewaxing and rehydration to distilled water, sections were subject to heat-induced target retrieval in 10 mM citrate buffer, pH 6 for 5 min at 750 W followed by 5 min at 450 W in a microwave oven. After cooling, the slides were washed in Tris-buffered saline pH 7.2 and subsequent staining steps were performed manually with the Dako EnVision þ System, Peroxidase (DAB), according to the manufacturer's instructions. Additionally, after blocking endogenous peroxidase activity, and prior to incubation with the primary antibody, the sections were incubated with 10% normal (nonimmune) goat serum (Dako) for 30 min. The mouse primary antibodies were anti-b-catenin antibody (clone 14, BD Transdunction Laboratories), anti-MLH1 (clone G168-15, Pharmingen), anti-MSH2 (clone FE-11, Calbiochem/Oncogene Research), anti-MSH6 (clone 44, Transduction Laboratories), anti-CDX2 (clone CDX2-88, BioGenex), and anti-p53 (clone DO7, DakoCytomation). Nonimmune mouse IgG1 (Dako) was used as negative control for mouse primary antibodies.
Paired tumor and normal mucosa were in the same section and the normal tissues were used as internal reference for evaluation of staining results. b-Catenin expression was considered aberrant if there was nuclear staining in more than 10% or cytoplasmic staining of more than 50% of tumor cells (not observed in the matching normal tissue). All cases reported as membranous showed 0% nuclear staining except 1 case (56:1) that showed around 8% nuclear staining. We used a 30% cutoff level of positive tumor cells in reporting p53 protein stabilization. This relatively high level was shown to be most informative in determining aberrant p53 overexpression (Fujiwara et al., 1998) .
MSI and LOH
MSI status was determined using the Bethesda panel (BAT25, BAT26, D5S346, D2S123, and D17S250; Boland et al., 1998) . Tumors with two or more unstable markers were considered as having high-degree microsatellite instability (MSI-H) and those with one unstable marker as low-degree microsatellite instability (MSI-L). A total of 11 dinucleotide markers (Table 4) , including three markers from the Bethesda panel, were analysed for LOH in informative cases (i.e. those heterozygous and not showing MSI). Primer sequence and PCR conditions are available at ftp://ftp.genethon.fr/pub/ Gmap/Nature-1995. The forward primers were fluorescently labeled with FAM and PCR products were run on ABI3730 sequencer/genotyper and results analysed using GeneMapper v3 software (Applied Biosystems, Europe). A sample was scored as showing LOH, if one of the alleles had decreased 40% or more, and putative LOH or allelic imbalance, if the decrease was 21-39% for one allele.
Mutation analysis
CTNNB1 exon 3 was screened for mutation by PCR-single strand conformation polymorphism (SSCP) analysis and sequencing using published primers (Kitaeva et al., 1997) . CDX2 exon 3 was sequenced for cases showing expression changes using primers for fragments 3a and 3b (Hinoi et al., 2003) . Sequence alterations in the KRAS codon 12-13 were screened for by PCR-SSCP analysis and direct sequencing (Deng et al., 2004) . BRAF exon 15 was PCR amplified using primers 15F (5 0 -TCATAATGCTTGCTCTGATAGGA-3 0 ) and 15R (5 0 -GGCCAAAAATTTAATCAGTGGA-3 0 ) followed by SSCP analysis and direct sequencing. TP53 exons 5-8 were analysed by PCR-SSCP followed by direct sequencing. In addition, TP53 exon 8 was sequenced in all cases.
CGH
CGH was performed and results were analysed essentially as described previously (El-Rifai et al., 1997) . Briefly, tumor DNA and reference DNA (genomic DNA from peripheral blood leukocytes from normal donors) were labeled by nick translation with fluorescein-iso-thiocyanate (FITC)-conjugated dCTP and dUTP (DuPont, Boston, MA, USA), and Texas Red-conjugated dCTP and dUTP (Dupont), respectively, to obtain fragments ranging from 600 to 2000 bp. The results were analysed using the ISIS digital image analysis system (MetaSystems GmbH, Altlussheim, Germany), based on an integrated high-sensitivity monochrome charge-coupled device (CCD) camera and automated CGH analysis software.
Statistical analysis
Statistical significance for differences between groups (P-value) was determined using Fisher's, w 2 or t-test as appropriate. All reported P-values were two-sided, and values less than 0.05 were considered significant.
